| Name | Title | Contact Details |
|---|
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
HomeCare Options is a Paterson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NantHealth is a transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system. NantHealth solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical and operational delivery with real time actionable clinical data, and promoting wellness for a healthier, happier world. We are building an integrated, evidence-based, omically-informed, personalized approach to the delivery of care and the development of next generation healthcare solutions. NantHealth is a subsidiary of NantWorks a company founded and led by Dr. Patrick Soon-Shiong. NantWorks is a convergence of next generation machine vision, object and voice recognition technologies, ultra-low power semiconductors, supercomputing, and advanced networks for the purpose of bringing the digital revolution to healthcare, commerce, and digital entertainment to an entirely new level. NantHealth envisions a world in which cutting-edge developments in science, technology, infrastructure and human ingenuity converge to advance one extraordinary mission: transforming healthcare for the benefit of every patient. We merge innovation with infrastructure; empowering more efficient and effective clinical decisions through advanced and actionable health information. By improving the accuracy and timeliness of data, we can deliver targeted healthcare intelligence for evolutionary personalized care. Our ultimate mission is to empower progress through uniquely informed decisions; to bring the impossible to life by harnessing the power of convergence for the well-being of humanity.
Eyecarrot’s goal is to power a global, data-driven, expert therapeutic network to transform how human Oculomotor Sensory performance is diagnosed, exercised and enhanced. The company is building Binovi, a universal, collaborative care platform that integrates software, hardware, data and the expert knowledge and insights of vision care professionals to help patients on a global scale.